Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-increasing, Randomized, Double-blind, Placebo-controlled, Single-dose/multiple-dose Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection in Healthy Chinese Subjects.

NCT06679998 is registered in ClinicalTrials.gov with Jiangsu Kanion Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT06679998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06679998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-increasing, Randomized, Double-blind, Placebo-controlled, Single-dose/multiple-dose Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection in Healthy Chinese Subjects.
Lead sponsor
Jiangsu Kanion Pharmaceutical Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 14, 2024
Completion date
March 26, 2026
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke (ais)